HC Wainwright Lifts Earnings Estimates for Benitec Biopharma

Benitec Biopharma Limited (NASDAQ:BNTC) – Analysts at HC Wainwright increased their FY2026 earnings per share estimates for Benitec Biopharma in a research note issued on Monday, November 24th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of ($1.00) per share for the year, up from their prior estimate of ($1.65). HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share.

Benitec Biopharma (NASDAQ:BNTC) last released its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.13.

Several other equities research analysts also recently issued reports on BNTC. Citizens Jmp boosted their price objective on shares of Benitec Biopharma from $20.00 to $22.00 and gave the stock a “market outperform” rating in a research note on Tuesday, November 4th. Zacks Research upgraded shares of Benitec Biopharma from a “strong sell” rating to a “hold” rating in a report on Friday, November 14th. JMP Securities set a $22.00 price target on shares of Benitec Biopharma in a research report on Tuesday, November 4th. Oppenheimer reissued an “outperform” rating and issued a $29.00 price objective (down from $35.00) on shares of Benitec Biopharma in a research report on Tuesday, September 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Benitec Biopharma currently has an average rating of “Moderate Buy” and a consensus target price of $25.33.

Benitec Biopharma Stock Down 1.1%

BNTC opened at $12.93 on Wednesday. Benitec Biopharma has a 1 year low of $9.49 and a 1 year high of $17.15. The firm has a 50 day moving average price of $14.37 and a 200 day moving average price of $13.71. The company has a debt-to-equity ratio of 0.01, a quick ratio of 54.67 and a current ratio of 54.67. The company has a market cap of $437.84 million, a PE ratio of -8.80 and a beta of 0.23.

Insider Activity

In other Benitec Biopharma news, Director Suvretta Capital Management, L purchased 1,481,481 shares of Benitec Biopharma stock in a transaction that occurred on Friday, November 7th. The stock was purchased at an average price of $13.50 per share, with a total value of $19,999,993.50. Following the completion of the acquisition, the director owned 9,538,175 shares of the company’s stock, valued at approximately $128,765,362.50. This trade represents a 18.39% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Informed Momentum Co LLC bought a new stake in shares of Benitec Biopharma in the 1st quarter worth about $512,000. MYDA Advisors LLC increased its holdings in Benitec Biopharma by 4.0% in the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company’s stock valued at $677,000 after buying an additional 2,000 shares during the last quarter. AWM Investment Company Inc. increased its holdings in Benitec Biopharma by 35.2% in the first quarter. AWM Investment Company Inc. now owns 137,977 shares of the biotechnology company’s stock valued at $1,795,000 after buying an additional 35,950 shares during the last quarter. Infinitum Asset Management LLC raised its stake in Benitec Biopharma by 435.7% during the first quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company’s stock valued at $14,636,000 after buying an additional 915,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in Benitec Biopharma during the 1st quarter worth approximately $597,000. 52.19% of the stock is owned by institutional investors and hedge funds.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.